CTOs on the Move

Genprex

www.genprex.com

 
Genprex (Nasdaq: GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes. Genprex`s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.genprex.com
  • 3300 Bee Cave Road Suite 650-227
    Austin, TX USA 78746
  • Phone: 877.774.4679

Executives

Name Title Contact Details
Hemant Kumar
Chief Manufacturing and Technology Officer Profile

Funding

Genprex raised $10M on 05/08/2018
Genprex raised $25M on 02/09/2021

Similar Companies

Aristea Therapeutics

Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases.

Acris Antibodies

Acris Antibodies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EnviroLogix

Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.

PDS Biotechnology

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body`s immune system in the fight against cancer and infectious disease.

Horizon Ag-Products

Horizon Ag-Products, LP is a science and research-driven producer of innovative plant health solutions. We specialize in naturally-derived plant health products for the global agricultural market. Horizon Ag-Products is not a fertilizer company. We mak...